Evidence map›Paper›PMID 10544612›Full record

ReviewMedizinische Klinik (Munich, Germany : 1983)1999

[Pathophysiologic significance of growth factors and new therapeutic concepts in cardiovascular disease].

S Rosenkranz, M Böhm, A Kazlauskas

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Medizinische Klinik (Munich, Germany : 1983), 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

S RosenkranzDivision of Basic Science, Schepens Eye Research Institute, Harvard Medical School, Boston, USA. rosenkranz@vision.eri.harvard.edu
M Böhm
A Kazlauskas
Harvard University · USUniversity of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peptide growth factors such as PDGF, FGF, VEGF, and TGF-beta play a critical role in the pathogenesis of cardiovascular diseases. In addition to their pathophysiological role in atherosclerosis and myocardial remodeling, growth factors also promote beneficial effects such as stimulation of angiogenesis and formation of collateral vessels in ischemic tissue. This review focuses on the mechanisms of action and signal relay cascades of peptide growth factors, and summarizes novel therapeutic approaches in cardiovascular medicine. These approaches include both inhibition of growth factors in order to suppress pathogenic processes, and stimulation of growth factors to promote their beneficial effects.

Indexed as

Cardiovascular DiseasesEndothelial Growth FactorsFibroblast Growth Factor 2Growth InhibitorsGrowth SubstancesHumansLymphokinesPlatelet-Derived Growth FactorSignal TransductionTransforming Growth Factor betaVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsEndothelial Growth FactorsFibroblast Growth Factor 2Growth InhibitorsGrowth SubstancesLymphokinesPlatelet-Derived Growth FactorTransforming Growth Factor betaVascular Endothelial Growth Factor AVascular Endothelial Growth Factors

Identifiers

PMID10544612
OpenAlexW302139339

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.